| 2.1 Subgroup analysis (type of antiplatelet agent): cyclooxygenase inhibitors or ADP receptor/P2Y12 inhibitors in participants with moderate to severe COVID‐19 |
3 |
17249 |
Risk Ratio (M‐H, Random, 95% CI) |
0.95 [0.89, 1.02] |
| 2.1.1 Cyclooxygenase inhibitor (acetylsalicylic acid) |
2 |
15859 |
Risk Ratio (M‐H, Random, 95% CI) |
0.96 [0.90, 1.02] |
| 2.1.2 P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) |
2 |
1390 |
Risk Ratio (M‐H, Random, 95% CI) |
1.02 [0.61, 1.69] |
| 2.2 Subgroup analysis: concomitant therapeutic dose anticoagulation or prophylactic anticoagulation |
3 |
15828 |
Risk Ratio (M‐H, Random, 95% CI) |
0.97 [0.83, 1.13] |
| 2.2.1 Antiplatelet agents plus standard care (including prophylactic anticoagulation) |
2 |
15024 |
Risk Ratio (M‐H, Random, 95% CI) |
0.92 [0.77, 1.10] |
| 2.2.2 Antiplatelet agents plus therapeutic anticoagulation |
2 |
804 |
Risk Ratio (M‐H, Random, 95% CI) |
1.27 [0.88, 1.84] |
